Adquey (difamilast)
Acrotech Biopharma
ApprovedFeb 12, 2026
Marketer take
A topical PDE4 inhibitor for mild-to-moderate atopic dermatitis, competing with Zoryve, Eucrisa and topical steroids for steroid-sparing positioning with dermatologists and pediatricians.
- Sponsor company
- Acrotech Biopharma
- Indication
- To treat mild to moderate atopic dermatitis
- Therapeutic area
- Dermatology
- Event
- FDA approval
- Date
- Feb 12, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?